San Diego-primarily based Viking Therapeutics marked by itself as a significant competitor in the weight loss drug sector in February following revealing promising knowledge from a mid-stage trial of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when provided for a weekly injection As well as in March